Innovative Treatments in Diabetes Type 1Bernadette Barbara Lenartowicz* and Emilian Snarski
Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland
- *Corresponding Author:
- Bernadette Barbara Lenartowicz
Department of Hematology
Oncology and Internal Medicine
Medical University of Warsaw
Independent Public Central Clinical Hospital
ul. Anacha 1a, 02-097 Warsaw, Poland
Tel: (22) 599-28-18
Fax: (22) 599-28-18
E-mail: [email protected]
Received date: September 14, 2012; Accepted date: October 30, 2012; Published date: November 05, 2012
Citation: Lenartowicz BB, Snarski E (2012) Innovative Treatments in Diabetes Type 1. J Diabetes Metab 3:224 doi:10.4172/2155-6156.1000224
Copyright: © 2012 Lenartowicz BB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Type 1 diabetes mellitus (T1DM) is a metabolic disease caused by autoimmune destruction of beta cells in the pancreas leading to insufficient production of insulin. The standard treatment of diabetes relies on multiple injections of insulin. One of the main drawbacks of this treatment is the inability to replicate timing and action on endogenous insulin secretion when beta cells are intact. Resulting hyper- and hypoglycemias cause long term and acute side effects of the disease. There are multiple approaches to overcome this problem: insulin pumps, oral insulin preparations, immunomodulatory treatments and transplantation of beta cells. This review summarizes recent advances in the treatment of diabetes.